1. 1) Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature, 445, 851–857 (2007).
2. 2) Balch CM, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol., 19, 3622–3634 (2001).
3. 3) DeSantis CE, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin., 64, 252–271 (2014).
4. 4) Sato Y, et al. Innovative Technologies in Nanomedicines: From Passive Targeting to Active Targeting/From Controlled Pharmacokinetics to Controlled Intracellular Pharmacokinetics. Macromol. Biosci., 17, (2017).
5. 5) Hoy SM. Patisiran: First Global Approval. Drugs, 78, 1625–1631 (2018).